European Journal of Cancer
Volume 41, Issue 14 , Pages 2102-2111 , September 2005

Costs of treatment intensification for head and neck cancer: Concomitant chemoradiation randomised for radioprotection with amifostine

  • Marijel Braaksma

      Affiliations

    • Department of Radiation Oncology, Erasmus Medical Center–Daniel den Hoed, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    • ,
  • Michel van Agthoven

      Affiliations

    • Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands
    • ,
  • Wideke Nijdam

      Affiliations

    • Department of Radiation Oncology, Erasmus Medical Center–Daniel den Hoed, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    • ,
  • Carin Uyl-de Groot

      Affiliations

    • Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands
    • ,
  • Peter Levendag

      Affiliations

    • Department of Radiation Oncology, Erasmus Medical Center–Daniel den Hoed, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 10 4391366; fax: +31 10 4391013.

Received 1 April 2005 ,Revised 6 May 2005 ,Accepted 13 May 2005.

References 

  1. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet. 2000;355:949–955
  2. Bourhis J, Audry J, Overgaard J, et al. Meta-analysis of conventional versus altered fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC): final analysis. Int J Radiat Oncol Biol Phys. 2004;60:190–191
  3. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomised study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 [see comments]. Int J Radiat Oncol Biol Phys 2000, 48, 7–16.
  4. Robbins KT, Kumar P, Wong FS, et al. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck. 2000;22:687–693
  5. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomised trials. J Clin Oncol. 1996;14:838–847
  6. Antonadou D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739–747
  7. Buntzel J, Kuttner K, Frohlich D, et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. [see comments] Ann Oncol. 1998;9:505–509
  8. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomised trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–3345
  9. van de Pol M, Levendag P, Franssen J, et al. Tumour control and functional outcome after radical surgery or interstitial radiotherapy-treatment options in T3/T4 cancer of the base of the tongue. Int J Radiat Oncol Biol Phys. 2002;54:292–293
  10. TNM Classification of malignant tumours. 5th edn. Wiley-Liss, New York, 1997.
  11. Braaksma M, Levendag P, De Jonge M, et al. Organ preservation with chemoradiation in advanced head and neck cancer concomitant paclitaxel with or without subcutaneous amifostine prior to radiation preliminary results on toxicity of a randomised clinical trial. Int J Radiat Oncol Biol Phys. 2002;54:291
  12. Shaw LM, Bonner HS, Schuchter L, et al. Pharmacokinetics of amifostine: effects of dose and method of administration. Semin Oncol. 1999;26:34–36
  13. Rades D, Fehlauer F, Bajrovic A, et al. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol. 2004;70:261–264
  14. Levendag P, Nijdam W, Agthoven van M, et al. Chemotherapy and high-dose-rate brachytherapy in the management of advanced cancers of the nasopharynx: clinical impact of high technology – is it worth the cost?. Brachytherapy. 2002;1:11–20
  15. Smith RV, Kotz T, Beitler JJ, et al. Long-term swallowing problems after organ preservation therapy with concomitant radiation therapy and intravenous hydroxyurea: initial results. Arch Otolaryngol Head Neck Surg. 2000;126:384–389
  16. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66:253–262
  17. Glatstein E. Intensity-modulated radiation therapy: the inverse, the converse, and the perverse. Semin Radiat Oncol. 2002;12:272–281
  18. Levendag P, Braaksma M, Coche E, et al. Rotterdam and Brussels CT-based neck nodal delineation compared with the surgical levels as defined by the American Academy of Otolaryngology-Head and Neck Surgery. Int J Radiat Oncol Biol Phys. 2004;58:113–123
  19. Drummond M, O’Brien B, Stoddart G, et al. Methods for the economic evaluation of heath care programmes, 1997.
  20. Nowak PJ, Wijers OB, Lagerwaard FJ, et al. A three-dimensional CT-based target definition for elective irradiation of the neck. Int J Radiat Oncol Biol Phys. 1999;45:33–39
  21. de Boer HC, van Sornsen de Koste JR, Creutzberg CL, et al. Electronic portal image assisted reduction of systematic set-up errors in head and neck irradiation. Radiother Oncol. 2001;61:299–308
  22. Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Semin Oncol. 2002;29:63–70
  23. Tishler RB, Busse PM, Norris CM, et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys. 1999;43:1001–1008
  24. Wijers OB, Levendag PC, Braaksma MM, et al. Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck. 2002;24:737–747
  25. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. [see comments] N Engl J Med. 1998;338:1798–1804
  26. Kaanders JH, van der Kogel AJ, Ang KK. Altered fractionation: limited by mucosal reactions?. Radiother Oncol. 1999;50:247–260
  27. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment?. Lancet Oncol. 2003;4:378–381
  28. van Agthoven M, van Ineveld BM, de Boer MF, et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer. 2001;37:2204–2211
  29. Nijdam W, Levendag P, Noever I, et al. Cost analysis comparing brachytherapy versus surgery for primary carcinoma of the tonsillar fossa and/or soft palate. Int J Radiat Oncol Biol Phys. 2004;59:488–494
  30. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck. 2003;25:1057–1070
  31. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck. 2004;26:77–84
  32. Biswal BM, Zakaria A, Ahmad NM. Topical application of honey in the management of radiation mucositis: a preliminary study. Support Care Cancer. 2003;11:242–248
  33. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004;22:4613–4621

PII: S0959-8049(05)00552-6

doi: 10.1016/j.ejca.2005.05.012

European Journal of Cancer
Volume 41, Issue 14 , Pages 2102-2111 , September 2005

Article Tools